Fragile X syndrome, or "Martin Bell syndrome," is an inherited disorder that causes symptoms similar to the autism spectrum and that, in many cases, also causes mental developmental disorders.
Fragile X syndrome is the most common inherited cause of autism and mental retardation. To date, despite the efforts of pharmaceutical companies, there is still no drug approved for treatment. A new study suggests that cannabidiol (CBD) treatment may be effective for people with the syndrome.
Fragile X syndrome (SXF) is a dominant X-linked disorder caused by a mutation in the mental retardation of fragile X. Cannabidiol (CBD) is an exogenous phytocannabinoid with therapeutic potential for sufferers anxiety, disorders sleep and deficits cognitive, as well as for populations suffering from endocannabinoid deficiencies, such as those suffering from SXF (a genetic disease caused by a mutation in the X chromosome). The objective of this study was to provide a brief narrative review of the recent literature on endocannabinoids and SXF and to present a series of cases describing three patients with SXF who were treated orally.
This study reveals the importance of exploring the therapeutic potential of CBD in the context of rigorous clinical trials.
Patients participating in the study received oral solutions of CBD orally from 32 to 63,9 mg. In two of the patients, symptoms worsened after stopping CBD and improved further after resumption of treatment.
The three patients described in the case series had functional benefits following the use of oral CBD solutions, including notable reductions in social exclusion and anxiety, as well as improved sleep, nutrition, motor coordination, language skills and sensory processing. Two of the patients described experienced a re-emergence of a number of symptoms of SXF after stopping treatment.
Rather, pharmacotherapy aims to relieve secondary symptoms of the disease, such as self-harm, aggression, depression and anxiety, and mainly includes antidepressants and antipsychotics.
"Previous studies have shown that many of the abnormal symptoms of fragile X syndrome are due to a lack of regulation of the endocannabinoid system and reduced stimulation of their receptors due to a lack of natural endocannabinoids for link to it. Studies have shown that consumption of CBD increases levels endocannabinoid anandamide and of AG-2, thereby reducing or even neutralizing one of the biological mechanisms of abnormal cell function in fragile X syndrome. "
Although a number of drugs have been developed to target specific systems (GABA agonists), CBD has the potential to produce a multifaceted effect for people with SXF due to its multiple benefits and mechanisms of action.